By Melissa Sturgess, CEO of Ananda Pharma A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor. This should be celebrated as a global success story and a key moment for UK innovation, but surprisingly, few companies are following in GW’s footsteps.